Noam Bar-Yaakov1,2, Ziv Savin1,2, Ibrahim Fahoum2,3, Sophie Barnes2,4, Yuval Bar-Yosef1,2, Ofer Yossepowitch1,2, Gal Keren-Paz1,2, Roy Mano1,2
Canadian Journal of Urology, Vol.31, No.1, pp. 11793-11801, 2024
Abstract Introduction: Prostate cancer screening with PSA
is associated with low specificity; furthermore, little is
known about the optimal timing of biopsy. We aimed to
evaluate whether a risk classification system combining
PSA density (PSAD) and mpMRI can predict clinically
significant cancer and determine biopsy timing.
Materials and methods: We reviewed the medical
records of 256 men with a PI-RADS ≥ 3 lesion on mpMRI
who underwent transperineal targeted and systematic
biopsies of the prostate between 2017-2019. Patients
were stratified into three risk groups based on PSAD and
mpMRI findings.
The study endpoint was clinically significant prostate
cancer (CSPC).… More >